Frank Lin - Publications, H-index & Citations

Frank Lin

the university of sydney

19H指数

109论文数

1.3K被引数

收录论文 26

发表时间

Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program 无进展生存时间比率作为早期肿瘤学临床试验的潜在研究终点：澳大利亚MoST计划II期试验的合并分析

Future Oncology

IF2.6

2026-06-16

OAAI

Derrick H. W. Siu; Frank P. Y. Lin; David M. Thomas; Subotheni Thavaneswaran; David Espinoza; Sarah Chinchen; Mandy L. Ballinger; R. John Simes; Chee Khoon Lee

Whole genome sequencing in oesophageal adenocarcinoma unmasks potential precision therapies 全基因组测序揭示食管腺癌的潜在精准治疗方案

BMC Cancer

IF3.4

2026-05-25

OAAI

Sowmya Sharma; Ho Yi Wong; Rebecca L Johnston; Lambros T Koufariotis; Scott Wood; Georgina Hollway; Lauren G Aoude; Aimee L Davidson; John V Pearson; Frank P Lin; Andrew P Barbour; Nicola Waddell

Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials TP53分类在先前接受过治疗的晚期驱动基因阴性非小细胞肺癌中的临床影响：OAK和POPLAR随机临床试验的生物标志物分析

Lung Cancer

IF4.4

2025-12-29

OAAI

Deborah Di-Xin Zhou; Sarah J. Lord; Frank Po-Yen Lin; Wendy A. Cooper; Milita Zaheed; Robert John Simes; Thomas John; Chee Khoon Lee

A signal-seeking phase 2 study of tremelimumab in advanced cancers with high tumour mutational burden 特瑞普利单抗在高度肿瘤突变负荷的晚期癌症中的一项信号探索性II期研究

npj Precision Oncology

IF8

2025-11-21

OAAI

Subotheni Thavaneswaran; Frank Lin; David Espinoza; John Grady; Peey-Sei Kok; Sarah Chinchen; Nick Pavlakis; Vladimir Andelkovic; Michail Charakidis; Paul Craft; Michael Brown; Jayesh Desai; Peter Lau; Maya Kansara; John Simes; David Thomas

PATH-52. Understanding the prevalence ofMTAP andCDKN2A/B deletion in gliomas by next generation sequencing PATH-52. 通过下一代测序了解MTAP和CDKN2A/B在胶质瘤中的缺失发生率

Neuro-Oncology

IF13.4

2025-11-11

OAAI

Natalie Southi; Hao-Wen Sim; John Grady; Laveniya Satgunaseelan; Min Huang; Maya Kansara; Alexander Yuile; Ashraf Zaman; Frank Lin; Helen Wheeler; Amanda Hudson; Mandy L Ballinger; David M Thomas; Subotheni Thavaneswaran

Multi-parametric profiling of IL-7-augmented GD2.CART products in a phase 1 clinical trial IL-7增强的GD2.CART产品在1期临床试验中的多参数分析

iScience

IF4.1

2025-10-06

OAAI

Sarah Schulenberg; Martí Farrera-Sal; Michelle Loeser; Lukas Ehlen; Stephan Schlickeiser; Samira Picht; Lena Peter; Marco Mai; Candise L. Tat; Jacqueline Keye; Desiree Kunkel; Frank Lin; Cliona M. Rooney; Bilal Omer; Michael Schmueck-Henneresse

Oncogenic mutations in the TP53 and PI-3 kinase/AKT pathway are independent predictors of survival for advanced thyroid cancer: Analysis from the Molecular Screening and Therapeutics (MoST) program

SURGERY

IF2.7

2025-01-01

PREAI

Novis, Elan; Glover, Anthony; Grady, John P.; Silvestri, Audrey; Thavaneswaran, Subotheni; Lin, Frank; Ballinger, Mandy L.; Thomas, David M.

A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation

NPJ PRECISION ONCOLOGY

IF8

2024-09-09

OAAI

Thavaneswaran, Subotheni; Lin, Frank; Grady, John P.; Espinoza, David; Huang, Min Li; Chinchen, Sarah; Sebastian, Lucille; Kansara, Maya; Mersiades, Tony; Lee, Chee Khoon; Desai, Jayesh; Grimison, Peter; Brown, Michael; Millward, Michael; Harrup, Rosemary; O'Byrne, Ken; Nagrial, Adnan; Craft, Paul; Simes, John; Joshua, Anthony M.; Thomas, David M.

Impact of symptom and functional burden on survival in pancreatic ductal adenocarcinoma (PDAC)症状和功能负担对胰腺导管腺癌（PDAC）生存期的影响

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Pitiyarachchi, O.; Lin, F. P.; Spooner, A.; Sharbeen, G.; Barker, H. P.; Thornton, K.; Collignon, E.; Ballinger, M. L.; Thomas, D. M.; Magenau, A.; Porazinski, S.; Raina, A.; Sjoquist, K. M.; Chantrill, L. A.; Gebski, V.; Sowmya, A.; Timpson, P.; Pajic, M.; Goldstein, D.; Phillips, P. A.

Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy Tucatinib和Trastuzumab在HER2突变或扩增的晚期癌症中的应用：一项分子筛查与治疗（MoST）计划亚研究

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Kong, B. Y.; Lin, F. P-Y.; Espinoza, D.; Thavaneswaran, S.; Meniawy, T.; Desai, J.; Harrup, R.; Selva-Nayagam, S.; Charakidis, M.; Cuff, K.; Sebastian, L.; Lee, C. K.; Chinchen, S.; Thomas, D. M.; Ballinger, M. L.; Simes, J.; Goldstein, D.

Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databases 通过来自药理学数据库的脱靶药物结合相互作用对肿瘤药物进行计算再利用

CLINICAL AND TRANSLATIONAL MEDICINE

IF6.8

2024-04-17

OAAI

Walpole, Imogen R.; Zaman, Farzana Y.; Zhao, Peinan; Marshall, Vikki M.; Lin, Frank P.; Thomas, David M.; Shackleton, Mark; Antolin, Albert A.; Ameratunga, Malaka

Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing 环状DNA纳米结构对Cas12a激活的拓扑障碍促进了自催化和转化DNA/RNA传感

NATURE COMMUNICATIONS

IF15.7

2024-03-05

OAAI

Deng, Fei; Li, Yi; Yang, Biyao; Sang, Rui; Deng, Wei; Kansara, Maya; Lin, Frank; Thavaneswaran, Subotheni; Thomas, David M.; Goldys, Ewa M.

Delivering Data-Driven Precision and Equitable Artificial Intelligence Decision Tools in Oncology: Exploring the Informarker Concept

JCO CLINICAL CANCER INFORMATICS

IF2.8

2023-09-01

OAAI

Lin, Frank P.

Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2023-07-10

OAAI

Zeverijn, Laurien J.; Looze, Eleonora J.; Thavaneswaran, Subotheni; Henegouwen, J. Maxime van Berge; Simes, Robert J.; Hoes, Louisa R.; Sjoquist, Katrin M.; van der Wijngaart, Hanneke; Sebastian, Lucille; Geurts, Birgit S.; Lee, Chee K.; de Wit, Gijsbrecht F.; Espinoza, David; Roepman, Paul; Lin, Frank P.; Jansen, Anne M. L.; de Leng, Wendy W. J.; van der Noort, Vincent; Leek, Lindsay V. M.; de Vos, Filip Y. F. L.; van Herpen, Carla M. L.; Gelderblom, Hans; Verheul, Henk M. W.; Thomas, David M.; Voest, Emile E.

Can cancer go green? It's up to us

FRONTIERS IN ONCOLOGY

IF3.3

2023-02-22

OAAI

Epstein, Richard J.; Gu, Yanfei; Lin, Frank P. Y.

Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab

MOLECULAR ONCOLOGY

IF4.5

2022-12-13

OAAI

Kansara, Maya; Bhardwaj, Neeru; Thavaneswaran, Subotheni; Xu, Chang; Lee, Jessica K.; Chang, Lo-Bin; Madison, Russell W.; Lin, Frank; Hsu, Eugene; Patel, Vipul Kumar; Aleshin, Alexey; Oxnard, Geoffrey R.; Simes, John; Nimeiri, Halla; Thomas, David M.

Development and Validation of a Machine Learning Approach Leveraging Real-World Clinical Narratives as a Predictor of Survival in Advanced Cancer

JCO CLINICAL CANCER INFORMATICS

IF2.8

2022-10-01

PREAI

Lin, Frank Po-Yen; Salih, Osama S. M.; Scott, Nina; Jameson, Michael B.; Epstein, Richard J.

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology

NPJ PRECISION ONCOLOGY

IF8

2021-06-23

OAAI

Lin, Frank P.; Thavaneswaran, Subotheni; Grady, John P.; Ballinger, Mandy; Kansara, Maya; Oakes, Samantha R.; Desai, Jayesh; Lee, Chee Khoon; Simes, John; Thomas, David M.

TEPAPA: a novel in silico feature learning pipeline for mining prognostic and associative factors from text-based electronic medical records

SCIENTIFIC REPORTS

IF3.9

2017-07-31

OAAI

Lin, Frank Po-Yen; Pokorny, Adrian; Teng, Christina; Epstein, Richard J.

Computational prediction of multidisciplinary team decision-making for adjuvant breast cancer drug therapies: a machine learning approach

BMC CANCER

IF3.4

2016-12-01

OAAI

Lin, Frank P. Y.; Pokorny, Adrian; Teng, Christina; Dear, Rachel; Epstein, Richard J.

研究方向